Research Papers

25 of 947 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-r…
Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR.
Wang X; Chen T; Li C; Li W; Zhou X; Li Y; Luo D; Zhang N; Chen B; Wang L; Zhao W; Fu S; Yang Q.
J Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y; Zhang H; Merkher Y; Chen L; Liu N; Leonov S; Chen Y.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Posttranslational control of lipogenesis in the tumor microenvironment.
Zhu Y; Lin X; Zhou X; Prochownik EV; Wang F; Li Y.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy.
Wang Y; Johnson KCC; Gatti-Mays ME; Li Z.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma …
Yu EY; Cheung NV; Lue NF.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chro…
Jiang Q; Li Z; Qin Y; Li W; Xu N; Liu B; Zhang Y; Meng L; Zhu H; Du X; Chen S; Liang Y; Hu Y; Liu X; Song Y; Men L; Chen Z; Niu Q; Wang H; Lu M; Yang D; Zhai Y; Huang X.
J Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF…
Zhang T; Xia W; Song X; Mao Q; Huang X; Chen B; Liang Y; Wang H; Chen Y; Yu X; Zhang Z; Yang W; Xu L; Dong G; Jiang F.
J Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Targeting macrophages in hematological malignancies: recent advances and future directions.
Li W; Wang F; Guo R; Bian Z; Song Y.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA.
Feng Z; Li K; Qin K; Liang J; Shi M; Ma Y; Zhao S; Liang H; Han D; Shen B; Peng C; Chen H; Jiang L.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumo…
Yan Y; Huang L; Liu Y; Yi M; Chu Q; Jiao D; Wu K.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype.
Su Y; Sun X; Liu X; Qu Q; Yang L; Chen Q; Liu F; Li Y; Wang Q; Huang B; Huang XJ; Zhang XH.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.
Jin P; Jiang J; Zhou L; Huang Z; Nice EC; Huang C; Fu L.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Emerging strategies to overcome resistance to third-generation EGFR inhibitors.
Shi K; Wang G; Pei J; Zhang J; Wang J; Ouyang L; Wang Y; Li W.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.
Zhu H; Gao H; Ji Y; Zhou Q; Du Z; Tian L; Jiang Y; Yao K; Zhou Z.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherap…
Xu L; Zou C; Zhang S; Chu TSM; Zhang Y; Chen W; Zhao C; Yang L; Xu Z; Dong S; Yu H; Li B; Guan X; Hou Y; Kong FM.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multice…
Zhao WH; Wang BY; Chen LJ; Fu WJ; Xu J; Liu J; Jin SW; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Zhang H; Bai J; Xu Y; Zhu H; Du J; Jiang H; Fan XH; Li JY; Hou J; Chen Z; Zhang WG; Mi JQ; Chen SJ; He AL.
J Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling.
Paskeh MDA; Entezari M; Mirzaei S; Zabolian A; Saleki H; Naghdi MJ; Sabet S; Khoshbakht MA; Hashemi M; Hushmandi K; Sethi G; Zarrabi A; Kumar AP; Tan SC; Papadakis M; Alexiou A; Islam MA; Mostafavi E; Ashrafizadeh M.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy …
Lew TE; Seymour JF.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y; Tang F; Wei YQ; Wei XW.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.
Eckardt JN; Stölzel F; Kunadt D; Röllig C; Stasik S; Wagenführ L; Jöhrens K; Kuithan F; Krämer A; Scholl S; Hochhaus A; Crysandt M; Brümmendorf TH; Naumann R; Steffen B; Kunzmann V; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause SW; Herbst R; Hänel M; Hanoun M; Kaiser U; Kaufmann M; Rácil Z; Mayer J; Kroschinsky F; Berdel WE; Ehninger G; Serve H; Müller-Tidow C; Platzbecker U; Baldus CD; Schetelig J; Bornhäuser M; Thiede C; Middeke JM.
J Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Tumor organoids: applications in cancer modeling and potentials in precision medicine.
Xu H; Jiao D; Liu A; Wu K.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Single-cell sequencing: a promising approach for uncovering the mechanisms of tumor metastasis.
Han Y; Wang D; Peng L; Huang T; He X; Wang J; Ou C.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ducta…
Liu Y; Shi M; He X; Cao Y; Liu P; Li F; Zou S; Wen C; Zhan Q; Xu Z; Wang J; Sun B; Shen B.
J Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
The dual role of autophagy in acute myeloid leukemia.
Seo W; Silwal P; Song IC; Jo EK.
J Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared